On November 19, Sinovac Biotech announced receiving a delisting determination letter from Nasdaq's Listing Qualifications Department due to its failure to submit the 2024 annual report by November 11, 2025. Although the company stated it would request a hearing to delay the delisting, the incident has once again exposed its long-standing corporate governance issues.
The resignation of auditing firm Grant Thornton in April 2025 directly led to the delayed annual report submission. Behind the auditor change lies a nearly decade-long battle for control. Since the initiation of privatization plans in 2016, founder Yin Weidong and rival Pan Ai’hua have engaged in fierce boardroom battles, including extreme actions such as seizing company seals and halting production lines, severely disrupting operations. In 2019, Nasdaq suspended its stock trading due to "corporate governance chaos," and now governance failures have resurfaced as a trigger for delisting.
**Control Dispute Escalates Financial and Operational Risks** The power struggle has not only impacted governance but also directly harmed financial stability. Since 2025, Sinovac has rolled out substantial dividend plans, including a $55-per-share cash payout and multiple special dividends. While some market observers interpreted these moves as "placating shareholders," they also raised concerns over liquidity and long-term sustainability.
Professor Deng Yong of Beijing University of Chinese Medicine noted that hefty dividends may temporarily boost confidence but could weaken R&D investment and risk resilience, potentially increasing future debt burdens. Financial reports show Sinovac’s H1 2024 revenue stood at $121.3 million with a net loss of $68.6 million, while cash reserves totaled $1.1 billion. Against volatile performance and material internal control deficiencies, the sustainability of such dividends remains questionable.
**Operating Fundamentals Under Pressure, Recovery Uncertain** Despite owning mature vaccine products for hepatitis A, influenza, and chickenpox, alongside progressing pipelines, Sinovac faces severe operational challenges. Annual revenue peaked at $19.4 billion in 2021 driven by COVID-19 vaccine sales but plummeted thereafter, with H1 2024 revenue down 13.6% YoY.
Meanwhile, R&D spending has dipped slightly, internal control flaws persist, and delisting risks loom. Whether Sinovac can achieve operational recovery amid governance chaos remains highly uncertain. A forced delisting would not only impair financing capacity and market credibility but could further erode investor confidence, exacerbating a vicious cycle for its business and finances.
**Conclusion** Sinovac’s delisting crisis, ostensibly triggered by auditor changes and reporting delays, reflects deeper systemic failures—protracted governance disputes, control battles, and strategic missteps. Resolving governance deadlocks while stabilizing operations will be pivotal to its survival.
This article incorporates AI-generated content.